Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ)

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with administering antiresorptive or antiangiogenic drugs. Despite significant research on MRONJ, its pathogenesis and effective treatments are still not fully understood. Animal models can be used to simulate the pathophysiological features of MRONJ, serving as standardized in vivo experimental platforms to explore the pathogenesis and therapies of MRONJ. Rodent models exhibit excellent effectiveness and high reproducibility in mimicking human MRONJ, but classical methods cannot achieve a complete replica of the pathogenesis of MRONJ. Modified rodent models have been reported with improvements for better mimicking of MRONJ onset in clinic. This review summarizes representative classical and modified rodent models of MRONJ created through various combinations of systemic drug induction and local stimulation and discusses their effectiveness and efficiency. Currently, there is a lack of a unified assessment system for MRONJ models, which hinders a standard definition of MRONJ-like lesions in rodents. Therefore, this review comprehensively summarizes assessment systems based on published peer-review articles, including new approaches in gross observation, histological assessments, radiographic assessments, and serological assessments. This review can serve as a reference for model establishment and evaluation in future preclinical studies on MRONJ.

References

[1] Ruggiero SL, . American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg., 2014, 72: 1938-1956.

[2] Yarom N, . Medication-related osteonecrosis of the Jaw: MASCC/ISOO/ASCO clinical practice guideline. J. Clin. Oncol., 2019, 37: 2270-2290.

[3] AlDhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the Jaw: A review. Cureus, 2020, 12: e6944.

[4] Rothweiler R, Voss PJ, Schmelzeisen R, Metzger MC. Medication-related osteonecrosis of the mandible: An unusual presentation and treatment. Int. J. Oral. Maxillofac. Surg., 2021, 50: 511-515.

[5] Poubel V, Silva CAB, Mezzomo LAM, De Luca Canto G, Rivero ERC. The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review. J. Craniomaxillofac Surg., 2018, 46: 245-256.

[6] Curra C, . Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model. Acta Cir. Bras., 2016, 31: 308-313.

[7] Vidal-Gutierrez X, Gomez-Clavel JF, Gaitan-Cepeda LA. Dental extraction following zoledronate, induces osteonecrosis in rat’s jaw. Med Oral. Patol. Oral. Cir. Bucal., 2017, 22: e177-e184.

[8] Tanaka J, . An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats. Oral. Dis., 2015, 21: 969-976.

[9] Zhou Y, . Combined administration of bisphosphonates, chemotherapeutic agents, and/or targeted drugs increases the risk for stage 3 medication-related osteonecrosis of the Jaw: A 4-year retrospective study. Biomed. Res. Int., 2020, 2020: 5847429.

[10] Yuce MO, Adali E, Isik G. The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clin. Oral. Investig., 2021, 25: 4529-4541.

[11] Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: A randomized clinical feasibility trial of drug holiday versus drug continuation. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio., 2022, 133: 165-173.

[12] Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The prevention of medication-related osteonecrosis of the Jaw. Dtsch. Arztebl. Int., 2017, 114: 63-69.

[13] Kang SH, Park SJ, Kim MK. The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction. J. Korean Assoc. Oral. Maxillofac. Surg., 2020, 46: 78-83.

[14] Kiho K, . Pulpal disease arising from medication-related osteonecrosis of the Jaw: A case report. J. Endod., 2020, 46: 1149-1154.

[15] Leite de Marcelos PGC, . The effects of zoledronic acid on the progression of experimental periodontitis in rats: Histological and microtomographic analyses. J. Periodontal. Implant Sci., 2021, 51: 264-275.

[16] Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone, 2021, 153: 116184.

[17] Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral. Oncol., 2009, 45: 164-172.

[18] Aghaloo TL, . Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Min. Res., 2011, 26: 1871-1882.

[19] Song M, . Preexisting periapical inflammatory condition exacerbates tooth extraction-induced bisphosphonate-related osteonecrosis of the Jaw lesions in mice. J. Endod., 2016, 42: 1641-1646.

[20] Aguirre JI, . Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J. Bone Min. Res., 2012, 27: 2130-2143.

[21] Messer JG, . Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis. Oral. Dis., 2019, 25: 1116-1135.

[22] Kim JY, Jang HW, Kim JI, Cha IH. Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats. Sci. Rep., 2021, 11

[23] Molez AM, . Effect of resveratrol on the progression of experimental periodontitis in an ovariectomized rat model of osteoporosis: Morphometric, immune-enzymatic, and gene expression analysis. J. Periodontal. Res., 2020, 55: 840-849.

[24] Liu J, . The effects of icariin on wound healing of extraction sites with administration of zoledronic and dexamethasone: A rat model study. J. Oral. Pathol. Med., 2018, 47: 198-205.

[25] Diaz DH, Rodas JA, Bozzini CE, Mandalunis PM, Escudero ND. Sequential administration of alendronate and strontium ranelate: Histomorphometry and bone biomechanics in ovariectomized animals. Acta Odontol. Latinoam., 2016, 29: 168-177.

[26] Kim JW, Tatad JCI, Landayan MEA, Kim SJ, Kim MR. Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease. Bone, 2015, 81: 442-448.

[27] Said F, . The effect of etidronate on the periodontium of ovariectomized rats. J. Periodontol., 2012, 83: 1063-1068.

[28] Li CL, Seneviratne CJ, Huo L, Lu WW, Zheng LW. Impact of actinomyces naeslundii on bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats with periodontitis. J. Craniomaxillofac. Surg., 2015, 43: 1662-1669.

[29] Toro LF, . Application of autologous platelet-rich plasma on tooth extraction site prevents occurence of medication-related osteonecrosis of the Jaws in rats. Sci. Rep., 2019, 9

[30] Biguetti CC, . Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization. PLoS One, 2019, 14: e0214173.

[31] Yu W, Su J. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice. Oral. Dis., 2020, 26: 609-620.

[32] Hadaya D, . Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis. J. Bone Min. Res, 2019, 34: 171-181.

[33] Messer JG, . Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. Bone, 2018, 108: 79-88.

[34] Kuroshima S, . Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Bone, 2018, 112: 177-186.

[35] Jabbour Z, do Nascimento C, El-Hakim M, Henderson JE, de Albuquerque Junior RF. Bacterial profile and bone healing in rats receiving cancer therapeutic doses of bisphosphonates and corticosteroids: a pilot study. Int. J. Oral. Maxillofac. Surg., 2016, 45: 1162-1169.

[36] Silva PG, . Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch. Oral. Biol., 2015, 60: 1237-1245.

[37] Hadaya D, . Development of medication-related osteonecrosis of the Jaw after extraction of teeth with experimental periapical disease. J. Oral. Maxillofac. Surg., 2019, 77: 71-86.

[38] Bolette A, . Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats. J. Craniomaxillofac Surg., 2019, 47: 349-356.

[39] Rao NJ, Wang JY, Yu RQ, Leung YY, Zheng LW. Role of periapical diseases in medication-related osteonecrosis of the Jaws. Biomed. Res. Int., 2017, 2017: 1560175.

[40] Cheong S, . Bisphosphonate uptake in areas of tooth extraction or periapical disease. J. Oral. Maxillofac. Surg., 2014, 72: 2461-2468.

[41] Kang B, . Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Min. Res., 2013, 28: 1631-1640.

[42] Kim T, . Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the Jaw-like lesion in mice. Am. J. Pathol., 2018, 188: 2318-2327.

[43] Khan AA, . Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J. Bone Min. Res., 2015, 30: 3-23.

[44] Xie D, . Sensory denervation increases potential of bisphosphonates to induce osteonecrosis via disproportionate expression of calcitonin gene-related peptide and substance P. Ann. N. Y Acad. Sci., 2021, 1487: 56-73.

[45] Jung J, . Effect and timing of parathyroid hormone analog administration for preventing medication-related osteonecrosis of the jaws in a murine model. J. Craniomaxillofac Surg., 2021, 49: 719-725.

[46] Huang J, Wang L, Tian WD. Small extracellular vesicles derived from adipose tissue prevent bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis. Int. J. Nanomed., 2021, 16: 3161-3172.

[47] de Sousa Ferreira VC, . Bisphosphonate-related osteonecrosis induced change in alveolar bone architecture in rats with participation of Wnt signaling. Clin. Oral. Investig., 2021, 25: 673-682.

[48] Watanabe J, . Extracellular vesicles of stem cells to prevent BRONJ. J. Dent. Res., 2020, 99: 552-560.

[49] Yadegari A, Aminzadeh A, Seyyedkhamesi S, Aminian M. The effect of melatonin on prevention of bisphosphonate-related osteonecrosis of the jaw: An animal study in rats. J. Korean Assoc. Oral. Maxillofac. Surg., 2020, 46: 266-274.

[50] Movila A, . Possible pathogenic engagement of soluble Semaphorin 4D produced by gammadeltaT cells in medication-related osteonecrosis of the jaw (MRONJ). Biochem. Biophys. Res. Commun., 2016, 480: 42-47.

[51] Hayano, H. et al. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. Bone 135, 115308 (2020).

[52] Tamaki, S. et al. Dynamic polarization shifting from M1 to M2 macrophages in reduced osteonecrosis of the jaw-like lesions by cessation of anti-RANKL antibody in mice. Bone 141, 115560 (2020).

[53] Wat, W. Z. M. Current controversies on the pathogenesis of medication-related osteonecrosis of the jaw. Dent. J. 4, 38 (2016).

[54] Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann. N. Y Acad. Sci., 2011, 1218: 47-54.

[55] Paulo, S. et al. Calcium phosphate ceramics can prevent bisphosphonate-related osteonecrosis of the jaw. Materials 13, 1955 (2020).

[56] Gol EB, Ozkan N, Bereket C, Onger ME. Extracorporeal shock-wave therapy or low-level laser therapy: Which is more effective in bone healing in bisphosphonate treatment?. J. Craniofac Surg., 2020, 31: 2043-2048.

[57] Rodriguez-Lozano, F. J. et al. Allogeneic bone marrow mesenchymal stem cell transplantation in tooth extractions sites ameliorates the incidence of osteonecrotic jaw-like lesions in zoledronic acid-treated rats. J. Clin. Med. 9, 1649 (2020).

[58] Alonso-Rodriguez E, . Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model. Med Oral. Patol. Oral. Cir. Bucal., 2019, 24: e529-e536.

[59] Sanda, K. et al. Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw. J. Periodontol. https://doi.org/10.1002/JPER.21-0294 (2021).

[60] Adachi N, . Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw. Sci. Rep., 2020, 10

[61] Buranaphatthana W, . Engineered osteoclasts resorb necrotic alveolar bone in anti-RANKL antibody-treated mice. Bone, 2021, 153: 116144.

[62] Monteiro CGJ, . Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy. Clin. Oral. Investig., 2021, 25: 6653-6659.

[63] Kushiro H, Takahashi H, Tanaka A. Effects of the prevention of medication-related osteonecrosis of the jaw by local administration of a dental pulp stem cell-conditioned medium to the rat tooth extraction socket. Odontology, 2021, 109: 836-844.

[64] Nakagawa T, . Effects of metformin on the prevention of bisphosphonate-related osteonecrosis of the jaw-like lesions in rats. J. Prosthodont. Res., 2021, 65: 219-224.

[65] Zhao D, . Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl Mater. Interfaces, 2020, 12: 44508-44522.

[66] Hokugo A, . Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice. Bone, 2019, 123: 115-128.

[67] Gao SY, . PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis. Bone, 2021, 144: 115117.

[68] Attar BM, Razavi SM, Daneshmand M, Davoudi A. Protective effects of resveratrol against osteonecrosis at the extraction site in bisphosphonate-treated rats. Int. J. Oral. Max Surg., 2020, 49: 1518-1522.

[69] Su Z, . Borate bioactive glass prevents zoledronate-induced osteonecrosis of the jaw by restoring osteogenesis and angiogenesis. Oral. Dis., 2020, 26: 1706-1717.

[70] Zandi M, Dehghan A, Amini P, Doulati S, Rezaeian L. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw. Clin. Oral. Investig., 2019, 23: 3987-3993.

[71] Ning HR, . Microfiber-reinforced composite hydrogels loaded with rat adipose-derived stem cells and BMP-2 for the treatment of medication-related osteonecrosis of the jaw in a rat model. ACS Biomater. Sci. Eng., 2019, 5: 2430-2443.

[72] Mergoni G, . Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats: A preliminary macroscopic and microscopic quantitative study. Med Oral. Patol. Oral. Cir. Bucal., 2019, 24: e339-e345.

[73] Soutome S, . Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci. Rep., 2021, 11

[74] Ueda N, . Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?. Clin. Oral. Investig., 2021, 25: 3087-3093.

[75] Soutome S, . Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?. PLoS One, 2018, 13: e0201343.

[76] Williams DW, . Indigenous microbiota protects against inflammation-induced osteonecrosis. J. Dent. Res., 2020, 99: 676-684.

[77] Soundia A, . Zoledronate impairs socket healing after extraction of teeth with experimental periodontitis. J. Dent. Res., 2018, 97: 312-320.

[78] Lorenzo-Pouso AI, . Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J. Oral. Pathol. Med., 2020, 49: 190-200.

[79] Aghaloo TL, . RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J. Bone Min. Res., 2014, 29: 843-854.

[80] Pacheco VN, . Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial. Int. J. Exp. Pathol., 2018, 99: 258-263.

[81] Rao NJ, Yu RQ, Wang JY, Helm A, Zheng LW. Effect of periapical diseases in development of MRONJ in immunocompromised mouse model. Biomed. Res. Int., 2019, 2019: 1271492.

[82] Castillo EJ, . Preventing or controlling periodontitis reduces the occurrence of osteonecrosis of the jaw (ONJ) in rice rats (Oryzomys palustris). Bone, 2021, 145: 115866.

[83] Messer JG, . Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris). Bone, 2020, 130: 115141.

[84] Messer JG, . Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis. Oral. Dis., 2019, 25: 1116-1135.

[85] Li CL, . Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin. Oral. Implants Res., 2016, 27: 1-6.

[86] Gkouveris I, . Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ). Bone, 2019, 123: 234-245.

[87] Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J, Tominaga K. Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int. J. Oral. Maxillofac. Surg., 2013, 42: 1481-1487.

[88] Inoue M, Matsumoto C, Nakajima K, Kuroshima S, Sawase T. Alendronate/dexamethasone combination therapy worsens soft and hard tissue wound healing around implants in rat maxillae. Bone, 2021, 148: 115942.

[89] Xia CW, . The feasibility of locating the affected bone of BRONJ with indocyanine green. Oral. Dis., 2020, 26: 1086-1089.

[90] Conte-Neto N, Bastos AS, Spolidorio LC, Marcantonio RA, Marcantonio E Jr. Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head. Face Med., 2011, 7: 7.

[91] Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J. Prosthodont Res., 2015, 59: 3-5.

[92] Mine, Y. et al. Occlusal trauma and bisphosphonate-related osteonecrosis of the jaw in mice. Calcif Tissue Int. https://doi.org/10.1007/s00223-021-00916-2 (2021).

[93] Razmara F, . Application of a collagen scaffold saturated with platelet-rich plasma in prevention of bisphosphonate-related osteonecrosis of the jaw in the rat animal model. Heliyon, 2021, 7: e06930.

[94] Paulo, S. et al. Calcium phosphate ceramics can prevent bisphosphonate-related osteonecrosis of the jaw. Materials 13, 1955 (2020).

[95] Ning H, . Microfiber-reinforced composite hydrogels loaded with rat adipose-derived stem cells and BMP-2 for the treatment of medication-related osteonecrosis of the jaw in a rat model. ACS Biomater. Sci. Eng., 2019, 5: 2430-2443.

[96] Huang J, Wang L, Tian W. Small extracellular vesicles derived from adipose tissue prevent bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis. Int. J. Nanomed., 2021, 16: 3161-3172.

[97] Soundia A, . Local RANKL delivery improves socket healing in bisphosphonate treated rats. Bone, 2021, 148: 115945.

[98] Liu J, . Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model. J. Periodontol., 2021, 92: 149-158.

[99] Sarkarat F, Modarresi A, Chiniforush N, Yazdanparast L, Rakhshan V. Efficacy of photodynamic therapy in minimizing bisphosphonate-related osteonecrosis of the jaws after dental extraction: A preliminary animal study. J. Oral. Maxillofac. Surg., 2019, 77: 307-314.

[100] Kim JW, Alfafara AMD, Kim HY, Kim SY, Kim SJ. Effects of pH alteration on the pathogenesis of medication-related osteonecrosis of the jaw. Bone, 2019, 122: 45-51.

[101] Brierly GI, . Investigation of sustained BMP delivery in the prevention of medication-related osteonecrosis of the jaw (MRONJ) in a rat model. Macromol. Biosci., 2019, 19: e1900226.

[102] Janovszky A, . Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats. Clin. Oral. Investig., 2015, 19: 1279-1288.

[103] Tamari T, . Endothelial progenitor cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. Sci. Rep., 2019, 9

[104] Wang JY, . Skeletal site-specific response of jawbones and long bones to surgical interventions in rats treated with zoledronic acid. Biomed. Res. Int., 2019, 2019: 5138175.

[105] Kosach GA, . Disorders of microcirculation in the mechanism of bisphosphonate osteonecrosis: Preliminary study in rats. Br. J. Oral. Maxillofac. Surg., 2020, 58: e38-e44.

[106] Yamamoto-Silva FP, Bradaschia-Correa V, Lima LA, Arana-Chavez VE. Ultrastructural and immunohistochemical study of early repair of alveolar sockets after the extraction of molars from alendronate-treated rats. Microsc. Res. Tech., 2013, 76: 633-640.

[107] Reier S, . Cross-modality imaging of bisphosphonate-treated murine jawbones. Analyst, 2021, 146: 4683-4699.

[108] Kim Y, Lee HY, Yoon HJ, Kim BS. Utility of 18F-fluorodeoxy glucose and 18F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: A preclinical study in a rat model. J. Craniomaxillofac Surg., 2016, 44: 357-363.

[109] Salgueiro M, . Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): A retrospective clinical study. EPMA J., 2019, 10: 21-29.

[110] Traboulsi-Garet B, . Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy. Clin. Oral. Investig., 2022, 26: 2371-2382.

[111] Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral. Oncol., 2009, 45: 164-172.

[112] Mawardi H, . A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J. Dent. Res., 2011, 90: 1339-1345.

[113] Mine Y, . Occlusal trauma and bisphosphonate-related osteonecrosis of the jaw in mice. Calcif. Tissue Int., 2022, 110: 380-392.

[114] Soma T, . Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw. J. Bone Min. Metab., 2021, 39: 372-384.

[115] Mikai, A. et al. BMP-2/beta-TCP local delivery for bone regeneration in MRONJ-like mouse model. Int. J. Mol. Sci. 21, 7028 (2020).

[116] Zhu W, . Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J., 2019, 33: 5208-5219.

[117] Erten Taysi A, . The efficacy of sustained-release chitosan microspheres containing recombinant human parathyroid hormone on MRONJ. Braz. Oral. Res., 2019, 33: e086.

[118] Cardoso, C. L. et al. Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: Microtomographic, microscopic, and immunohistochemical analyses. Brazilian Oral Res. 33, e050 (2019).

[119] Kuroshima S, . Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice. Stem Cell Res. Ther., 2019, 10: 209.

[120] Imada M, . Prevention of tooth extraction-triggered bisphosphonate-related osteonecrosis of the jaws with basic fibroblast growth factor: An experimental study in rats. PLoS One, 2019, 14: e0211928.

[121] Liu SS, . Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats. J. Periodontol., 2019, 90: 1449-1456.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81921002, 81900970, 81900970)